Introduction
The recent use of Bacillus anthracis as an agent of bioterrorism in the United States 1 has generated renewed interest in the antimicrobial susceptibility patterns of this organism. Current recommendations for treatment and prophylaxis for anthrax are based on limited data from animal experiments and historical reports. 2 The possibility exists that antibiotic-resistant strains of B. anthracis might be used as bioterrorism agents, although the recent attacks did not employ such strains. Another factor considered in treatment recommendations is the production of constitutive or inducible β-lactamases. In vitro resistance to penicillin, 3,4 cefuroxime 3,5 and extended-spectrum cephalosporins [4] [5] [6] has been reported, but penicillin resistance is not consistently associated with β-lactamase production. 3, 4 At the present time, fluoroquinolones or doxycycline are advocated as first-line agents for prophylaxis or treatment following exposure to spores, 1 in combination with additional agents for therapy of inhalational or other serious forms of anthrax. Therapy may be altered appropriately (for example, to include penicillin) when the antibiotic susceptibility profile of the infecting isolate becomes known. Other agents that are generally active in vitro against B. anthracis, but that are not necessarily clinically useful, include clindamycin, rifampicin, imipenem, chloramphenicol, vancomycin, cefazolin, tetracycline, linezolid, macrolides and aminoglycosides. 2 We tested the susceptibility of southern African strains of B. anthracis to several conventional and newly developed antimicrobials.
Materials and methods

B. anthracis isolates and control organisms
Two B. anthracis isolates were obtained from human infections acquired in Zimbabwe; the Sterne vaccine strain, 34F2, was a gift of Dr M. Henton, Onderstepoort Veterinary Research Institute (OVRI), Pretoria; NCTC 2606 was a culture collection isolate from the UK; all the other isolates were from domestic or wild animals in southern Africa, donated by Dr M. Henton (OVRI). Isolates had been stored in semi-solid agar; purity was checked by plating onto horse blood agar. The control organisms used were Staphylococcus aureus ATCC 29213 and Bacillus cereus ATCC 11778.
Antibiotics tested
Clarithromycin, erythromycin, cefdinir, cefditoren, ciprofloxacin, temafloxacin, tosufloxacin and the experimental agents cethromycin (ABT 773, 
Determination of antimicrobial susceptibility
We used the agar dilution method to determine MICs, according to the method of the National Committee for Clinical Laboratory Standards (NCCLS). 7 All work with bacteria was done in a class 2 biosafety cabinet in the biosafety level 3 laboratory of the National Health Laboratory Service, Johannesburg, South Africa. Inocula of B. anthracis were prepared by subculturing several colonies of an overnight growth on blood agar into trypticase soy broth, incubating at 37°C for 4-6 h, and adjusting the turbidity to the equivalent of a 0.5 McFarland standard. A multipoint replicator with 3 mm diameter pins was used to inoculate MuellerHinton agar with an estimated final inoculum size of 10 4 cfu/spot. 7 For each antimicrobial tested, growth control plates without incorporated antimicrobials were similarly inoculated. Incubation was at 37°C for 18-20 h. The MICs at which 50% and 90% of isolates were inhibited (MIC 50 and MIC 90 , respectively) were determined.
β-Lactamase detection
We used the chromogenic cephalosporin method (Nitrocefin: Oxoid, Basingstoke, UK) to test for constitutive β-lactamase production. Nitrocefin solution (four drops) was added to overnight 1 mL nutrient broth cultures of the B. anthracis isolates; the presence of a red colour on inspection after 30 min of incubation at 37°C indicated a positive reaction. A β-lactamase-producing Branhamella catarrhalis strain was used as a positive control.
Results and discussion
The results of the antimicrobial susceptibility testing are shown in Table 1 . The MICs for the S. aureus ATCC 29213 control strain were within the expected limits for previously characterized antibiotics. 7 The MIC 50 of erythromycin for B. anthracis was 1 mg/L, consistent with that reported for the US strain associated with the recent bioterrorism events. 6 The enhanced activity of clarithromycin, an agent recommended for secondary use in combination with either ciprofloxacin or doxycycline, was confirmed in our group of isolates, with an MIC 50 of 0.125 mg/L, similar to that of recent US isolates (0.25 mg/L). 6 These data support the view that anthrax strains are of intermediate susceptibility to the macrolides. The activity of the ketolide cethromycin (ABT 773) was however similar to that of the most active agents tested (the fluoroquinolones). There are to date no other published reports of the activity of this class of agent against the anthrax bacillus. The high MICs of the cephalosporins were in keeping with previous reports of β-lactamase production 3 and poor activity of cephalosporins 3-6 against B. anthracis. Five of our B. anthracis strains were constitutively β-lactamase producing, but the range of cephalosporin MICs (1-16 mg/L) for these strains was essentially the same as for the β-lactamase-negative isolates.
The activity of the other antimicrobials tested was in line with that of ciprofloxacin-the only one that appeared to be active at higher dilution was the (now withdrawn) agent tosufloxacin. The limitations of the use of the fluoroquinolones for anthrax prophylaxis and therapy are the potential for the emergence of resistance, 8, 9 the potential for relapse after even 30 days of prophylaxis 10 in a non-human primate model, and the potential for toxicity in long-term use of this class of agent. Recent data show evidence of the selection of quinolone, macrolide and tetracycline resistance after sequential exposures of anthrax organisms to these drugs. 9 Doxycycline, a recommended first line antibiotic for anthrax, was highly active against these strains of B. anthracis (MICs of 0.063 mg/L). Shown separately in Table 1 are the MICs for the 34F2 Sterne strain; this is an attenuated live vaccine strain that has been used to study antibiotic resistance in B. anthracis 8, 9 and although of low virulence, it is a potential infectious risk.
The data in this report would therefore support the further evaluation of both cethromycin (ABT 773) and ABT 492 against anthrax in animal models. The priority may be justifiably given to ABT 773 on the basis that it represents a new class of agent with activity against this pathogen.
